Risks and Management of Dyslipidemia

Jeong Han Saem
Public Relations Committee, The Korean Society of Lipid and Atherosclerosis/Heart Diseases Research Institute, Dr.Jeong’s Heart Clinic

Research has shown that dyslipidemia, a broad term that refers to several lipid disorders,  is a major global health burden. In particular, this study has focused on the management of dyslipidemia in Korea. In Korea, treatment algorithms were recently published by the Korean Society of Lipid and Atherosclerosis (KSoLA). With this standardized approach to medical healthcare, practitioners can raise awareness of the risks of dyslipidemia and educate the public on how to manage dyslipidemia. In addition, it is generally accepted that although healthy blood lipid levels vary, individuals with high levels of low-density lipoprotein cholesterol (LDL-C) and triglycerides or low high-density lipoprotein cholesterol (HDL-C) levels are at a higher risk of developing atherosclerosis, an important risk factor for cardiovascular disease. Unfortunately, there are no specific symptoms or manifestations, and most people with dyslipidemia are unaware that they have it. When treatment is provided, strategies for dyslipidemia vary depending on the patient`s underlying status and the primary target is to reduce the level of LDL-C to reduce future major adverse cardiovascular events. Furthermore, high cholesterol is usually treated with statins, which interfere with the production of cholesterol in the liver. In addition, statin possesses pleiotropic effects. Based on the treatment guidelines in Korea, the strategy is dependent on the patient`s cardiovascular risks and stat in therapy is the principal drug for management of dyslipidemia.
 
Keywords: Dyslipidemia, Risk, Management, Statin, Guideline